Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
Launched by M.D. ANDERSON CANCER CENTER · Mar 25, 2019
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping patients with medullary thyroid cancer and their caregivers make important decisions about their treatment options. The researchers are developing a tool, called a patient decision aid, that will provide information and support for when to start or stop new medications, join clinical trials, or continue regular monitoring of the cancer. The goal is to empower patients and their families to make informed choices and communicate their preferences effectively with their doctors.
To participate in this trial, you need to be at least 18 years old and either have medullary thyroid cancer, be a caregiver for someone with this condition, or be a healthcare provider who treats these patients. Participants will be asked to engage with the decision aid and share their experiences. It’s important to note that individuals with severe cognitive or psychological issues are not eligible to join. This study is currently recruiting participants, and it aims to improve the decision-making process for those affected by this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 years old or older
- • Have or will face(d) this decision, including: Patient/survivor - who has medullary thyroid carcinoma, as determined by a clinician or documented in the Genetics of Endocrine Neoplasia Registry or sporadic (medullary thyroid carcinoma) MTC database; Caregiver/family member - of patient/survivor who has medullary thyroid carcinoma, as nominated by the patient/survivor; and Provider - who treats patients/survivors who have medullary thyroid carcinoma, as described above
- • Able to speak, read, and write English
- • Pregnant patients are included
- Exclusion Criteria:
- • --Individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness; as documented in the registry)
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Elizabeth G Grubbs, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials